Provided by Tiger Trade Technology Pte. Ltd.

Keros Therapeutics, Inc.

17.57
+0.33001.91%
Post-market: 17.570.00000.00%17:08 EST
Volume:305.49K
Turnover:5.37M
Market Cap:535.29M
PE:11.16
High:17.90
Open:17.45
Low:17.35
Close:17.24
52wk High:22.55
52wk Low:9.12
Shares:30.47M
Float Shares:22.55M
Volume Ratio:1.13
T/O Rate:1.35%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.57
EPS(LYR):-5.0044
ROE:10.43%
ROA:4.40%
PB:0.76
PE(LYR):-3.51

Loading ...

Company Profile

Company Name:
Keros Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
2015
Employees:
82
Office Location:
1050 Waltham Street,Suite 302,Lexington,Massachusetts,United States
Zip Code:
02421
Fax:
- -
Introduction:
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical need in the United States. The company's lead protein therapeutic product candidate KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-047, a small molecule product candidate that is in Phase II clinical trials for the treatment of functional iron deficiency; and KER-012, which is in Phase II clinical trials to treat pulmonary arterial hypertension and cardiovascular disorders. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Directors

Name
Position
Jasbir Seehra
President, Chief Executive Officer and Director
Alpna Seth
Independent Director
Carl Gordon
Independent Director
Jean Jacques Bienaime
Chair
Julius Knowles
Independent Director
Mary Ann Gray
Independent Director
Nima Farzan
Independent Director

Shareholders

Name
Position
Jasbir Seehra
President, Chief Executive Officer and Director
Esther Cho
Senior Vice President, General Counsel
Keith Regnante
Chief Financial Officer and Principal Accounting Officer
Lorena Lerner
Chief Scientific Officer